Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2012 2
2013 2
2016 2
2018 3
2019 1
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

11 results
Results by year
Filters applied: . Clear all
Page 1
A Pre-Clinical Assessment of the Pan-ERBB Inhibitor Dacomitinib in Pediatric and Adult Brain Tumors.
Endersby R, Whitehouse J, Hii H, Greenall SA, Johns TG, Gottardo NG. Endersby R, et al. Among authors: greenall sa. Neoplasia. 2018 May;20(5):432-442. doi: 10.1016/j.neo.2018.02.004. Epub 2018 Mar 22. Neoplasia. 2018. PMID: 29574250 Free PMC article.
Most clinical anti-EGFR antibodies do not neutralize both wtEGFR and EGFRvIII activation in glioma.
Greenall SA, McKenzie M, Seminova E, Dolezal O, Pearce L, Bentley J, Kuchibhotla M, Chen SC, McDonald KL, Kornblum H, Endersby R, Adams TE, Johns TG. Greenall SA, et al. Neuro Oncol. 2019 Apr 19;21(8):1016-27. doi: 10.1093/neuonc/noz073. Online ahead of print. Neuro Oncol. 2019. PMID: 31002307 Free PMC article.
EGFRvIII: the promiscuous mutation.
Greenall SA, Johns TG. Greenall SA, et al. Cell Death Discov. 2016 Jul 4;2:16049. doi: 10.1038/cddiscovery.2016.49. eCollection 2016. Cell Death Discov. 2016. PMID: 27551537 Free PMC article. No abstract available.
Differential Sensitivity of Human Hepatocellular Carcinoma Xenografts to an IGF-II Neutralizing Antibody May Involve Activated STAT3.
Greenall SA, Donoghue J, Johns TG, Adams TE. Greenall SA, et al. Transl Oncol. 2018 Aug;11(4):971-978. doi: 10.1016/j.tranon.2018.05.011. Epub 2018 Jun 22. Transl Oncol. 2018. PMID: 29933129 Free PMC article.
Activation of ERBB4 in Glioblastoma Can Contribute to Increased Tumorigenicity and Influence Therapeutic Response.
Donoghue JF, Kerr LT, Alexander NW, Greenall SA, Longano AB, Gottardo NG, Wang R, Tabar V, Adams TE, Mischel PS, Johns TG. Donoghue JF, et al. Among authors: greenall sa. Cancers (Basel). 2018 Jul 25;10(8):243. doi: 10.3390/cancers10080243. Cancers (Basel). 2018. PMID: 30044378 Free PMC article.
Antibody fragments, expressed by a fowl adenovirus vector, are able to neutralize infectious bursal disease virus.
Greenall SA, Tyack SG, Johnson MA, Sapats SI. Greenall SA, et al. Avian Pathol. 2010 Oct;39(5):339-48. doi: 10.1080/03079457.2010.507239. Avian Pathol. 2010. PMID: 20954010
Incomplete target neutralization by the anti-cancer antibody rilotumumab.
Greenall SA, Adams TE, Johns TG. Greenall SA, et al. MAbs. 2016;8(2):246-52. doi: 10.1080/19420862.2015.1122149. MAbs. 2016. PMID: 26750997 Free PMC article.
Non-agonistic bivalent antibodies that promote c-MET degradation and inhibit tumor growth and others specific for tumor related c-MET.
Greenall SA, Gherardi E, Liu Z, Donoghue JF, Vitali AA, Li Q, Murphy R, Iamele L, Scott AM, Johns TG. Greenall SA, et al. PLoS One. 2012;7(4):e34658. doi: 10.1371/journal.pone.0034658. Epub 2012 Apr 12. PLoS One. 2012. PMID: 22511956 Free PMC article.
Glioma Specific Extracellular Missense Mutations in the First Cysteine Rich Region of Epidermal Growth Factor Receptor (EGFR) Initiate Ligand Independent Activation.
Ymer SI, Greenall SA, Cvrljevic A, Cao DX, Donoghue JF, Epa VC, Scott AM, Adams TE, Johns TG. Ymer SI, et al. Among authors: greenall sa. Cancers (Basel). 2011 Apr 18;3(2):2032-49. doi: 10.3390/cancers3022032. Cancers (Basel). 2011. PMID: 24212795 Free PMC article.
Effects of gefitinib, an epidermal growth factor receptor inhibitor, on human placental cell growth.
Nilsson UW, Johns TG, Wilmann T, Kaitu'u-Lino T, Whitehead C, Dimitriadis E, Menkhorst E, Saglam B, Gao Y, Greenall SA, Horne AW, Tong S. Nilsson UW, et al. Among authors: greenall sa. Obstet Gynecol. 2013 Oct;122(4):737-44. doi: 10.1097/AOG.0b013e3182a1ba56. Obstet Gynecol. 2013. PMID: 24084529
11 results
Jump to page